InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies. The company offers minimally-invasive aesthetic medical products for procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. InMode Ltd. offers its products directly in the United States, Canada, the United Kingdom, Spain, and India, as well as indirectly through third-party distributors internationally. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Phone972-4909-6313
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$100.16 million
Profitability
Miscellaneous
Employees198
Next Earnings Date2/4/2020 (Estimated)
OptionableNot Optionable
InMode (NASDAQ:INMD) Frequently Asked Questions
What is InMode's stock symbol?
InMode trades on the NASDAQ under the ticker symbol "INMD."
How were InMode's earnings last quarter?
InMode Ltd. (NASDAQ:INMD) issued its quarterly earnings data on Tuesday, November, 5th. The healthcare company reported $0.42 EPS for the quarter, topping analysts' consensus estimates of $0.29 by $0.13. The healthcare company earned $40.01 million during the quarter, compared to analyst estimates of $35.74 million. InMode had a return on equity of 50.50% and a net margin of 30.33%. The company's revenue for the quarter was up 57.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.26 EPS. View InMode's Earnings History.
When is InMode's next earnings date?
What price target have analysts set for INMD?
4 brokers have issued 12 month price targets for InMode's stock. Their forecasts range from $28.00 to $45.00. On average, they anticipate InMode's stock price to reach $37.00 in the next year. This suggests that the stock has a possible downside of 25.2%. View Analyst Price Targets for InMode.
What is the consensus analysts' recommendation for InMode?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InMode in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for InMode.
Has InMode been receiving favorable news coverage?
Media headlines about INMD stock have trended somewhat negative on Friday, according to InfoTrie. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. InMode earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave headlines about the healthcare company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for InMode.
Who are some of InMode's key competitors?
Some companies that are related to InMode include GETINGE AB/ADR (GNGBY), LivaNova (LIVN), CONMED (CNMD), Natus Medical (NTUS), AxoGen (AXGN), Cutera (CUTR), TransMedics Group (TMDX), BioLife Solutions (BLFS), Zynex (ZYXI), Semler Scientific (SMLR), Viewray (VRAY), Stereotaxis (STXS), BioSig Technologies (BSGM), Edap Tms (EDAP) and Fonar (FONR).
What other stocks do shareholders of InMode own?
Who are InMode's key executives?
InMode's management team includes the folowing people:
- Mr. Moshe Mizrahy, Chairman & CEO (Age 66)
- Mr. Yair Malca, Chief Financial Officer (Age 41)
- Dr. Michael Kreindel, CTO & Director (Age 51)
- Mr. Shakil Lakhani, Pres of North America (Age 35)
- Dr. Spero Theodorou, Chief Medical Officer (Age 47)
When did InMode IPO?
(INMD) raised $75 million in an IPO on Thursday, August 8th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Barclays, UBS Investment Bank and Canaccord Genuity acted as the underwriters for the IPO and Baird was co-manager.
When does InMode's lock-up period expire?
InMode's lock-up period expires on Tuesday, February 4th. InMode had issued 5,000,000 shares in its initial public offering on August 8th. The total size of the offering was $70,000,000 based on an initial share price of $14.00. After the expiration of InMode's lock-up period, major shareholders and company insiders will be able to sell their shares of the company.
Who are InMode's major shareholders?
InMode's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Rice Hall James & Associates LLC (0.18%), Dean Capital Investments Management LLC (0.14%), Emerald Advisers LLC (0.08%), Alpine Woods Capital Investors LLC (0.06%), D.A. Davidson & CO. (0.04%) and Steward Partners Investment Advisory LLC (0.02%).
Which major investors are buying InMode stock?
INMD stock was acquired by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, Dean Capital Investments Management LLC, Emerald Advisers LLC, Alpine Woods Capital Investors LLC, D.A. Davidson & CO., Steward Partners Investment Advisory LLC, Tower Research Capital LLC TRC and Patriot Financial Group Insurance Agency LLC.
How do I buy shares of InMode?
Shares of INMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is InMode's stock price today?
One share of INMD stock can currently be purchased for approximately $49.44.
How big of a company is InMode?
What is InMode's official website?
How can I contact InMode?
InMode's mailing address is TAVOR BUILDING SHAAR YOKNEAM POB 533, YOKNEAM L3, 2069200. The healthcare company can be reached via phone at 972-4909-6313 or via email at [email protected]
MarketBeat Community Rating for InMode (NASDAQ INMD)
MarketBeat's community ratings are surveys of what our community members think about InMode and other stocks. Vote "Outperform" if you believe INMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
